Survivor Julie Cohen discusses her experience with cevostamab, managing CRS side effects, and reaching MRD-negative status through a clinical trial.
Julie Cohen
Advertisement
Articles by Julie Cohen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
FDA Approves Tecentriq Plus Chemotherapy for Stage 3 dMMR Colon Cancer
3
5 Years of Liver Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
4